CurrentCignaPolicy IP0277

Penicillamine (Cuprimine, Depen, and generics) Coverage Policy

Cigna coverage policy for penicillamine products (Cuprimine, Depen, and generics) specifying medical necessity, reauthorization, authorization duration, and conditions not covered for insured individuals.

Policy Summary

PayerCigna

PolicyPenicillamine (Cuprimine, Depen, and generics) Coverage Policy

Policy CodePolicy IP0277

Change TypeNo material changes

Effective Date5/1/2025

Next Review Date

Key ActionObtain prior authorization and submit documentation confirming diagnostic criteria and required trials or contraindications (e.g., zinc trial for Wilson's disease) as specified.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3Indications listed

3Primary covered diagnoses

12 monthsApproval duration

NCApplicable state

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Wilson's Disease Coverage Criteria: A. Diagnosis of Wilson's disease confirmed by documentation of ONE of the following: (i) genetic testing results confirming biallelic pathogenic ATP7B mutations OR (ii) at least TWO of: (a) presence of Kayser-Fleischer rings; (b) serum ceruloplasmin < 20 mg/dL; (c) liver biopsy findings consistent with Wilson disease; (d) 24-hour urinary copper > 40 μg/24 hours. B. Documentation of ONE of the following: (i) failure, contraindication, or intolerance to zinc acetate capsules (Galzin) or another zinc product; (ii) prescriber documents the individual is symptomatic and zinc would not be appropriate; (iii) patient has been started on therapy with a penicillamine product. C. Medication is prescribed by, or in consultation with, a gastroenterologist, hepatologist, or liver transplant physician. D. Preferred product criteria are met for the product(s) as listed in the policy.

Cystinuria

Covered when ALL of the following are met:

Cystinuria Coverage Criteria: A. Documented failure or inability to adhere to conservative measures including increased fluid intake, restriction of sodium and protein intake, and urinary alkalinization. B. Preferred product criteria are met for the product(s) as listed in the policy.

Lead Poisoning

Covered when ALL of the following are met:

Lead Poisoning Coverage Criteria: A. Documentation of a blood lead level greater than 44 μg/dL. B. Documentation of failure, contraindication, or intolerance to BOTH: (i) succimer (Chemet) AND (ii) edetate calcium disodium (Calcium Disodium Versenate). C. Preferred product criteria are met for the product(s) as listed in the policy.

Coding and Key Clinical Thresholds

inv-06: Blood lead level — > 44 μg/dL

ThresholdBlood lead level > 44 μg/dL

Associated coverage criterionLead poisoning: required for medical necessity determination

Required prior stepsDocumentation of failure/contraindication/intolerance to succimer and edetate calcium disodium also required

inv-07: Serum ceruloplasmin — < 20 mg/dL

ThresholdSerum ceruloplasmin < 20 mg/dL

Role in diagnosisOne of the criteria: when <20 mg/dL it counts as one of two clinical features supporting Wilson's disease diagnosis

Source guidanceListed in AASLD diagnostic criteria referenced in policy

inv-08: 24-hour urinary copper — > 40 μg/24 hours

Threshold24-hour urinary copper > 40 μg/24 hours

Role in diagnosisCounts as one of two clinical features needed to confirm Wilson's disease if genetic testing not provided

Units clarificationExpressed as micrograms per 24 hours (μg/24 hours)

Provider Actions and Requirements

Prior Authorization

Prior Authorization Requirements

Prior authorization is required for product switches between penicillamine formulations as specified by the member's plan. For Employer Plans: switching to Cuprimine (capsules) or Depen (tablets) may require prior authorization when the request is due to a formulation difference in inactive ingredients causing a significant allergy or serious adverse reaction. For Individual and Family Plans: prior authorization is required when coverage is requested after documentation of failure, contraindication, or intolerance to the alternate penicillamine formulation.

Employer Plans: Prior authorization may be required when switching formulations due to inactive-ingredient allergy or serious adverse reaction.
Individual and Family Plans: Prior authorization required when documenting failure, contraindication, or intolerance to the alternate penicillamine formulation.

Step Therapy

Step Therapy for Wilson's Disease

Step therapy is required for Wilson's disease. A trial and documentation of failure, contraindication, or intolerance to zinc therapy (e.g., zinc acetate or other zinc products) must be provided unless the prescriber documents that the patient is symptomatic and zinc is not appropriate or the patient has already been started on a penicillamine product.

Zinc trial required (trial and failure/contraindication/intolerance) unless prescriber documents symptomatic disease where zinc is inappropriate.
Documentation that therapy with penicillamine has already been started satisfies the step requirement.

Documentation Required

Required Documentation

Providers must submit documentation to support medical necessity. For Wilson's disease include diagnostic confirmation (genetic testing showing biallelic pathogenic ATP7B mutations OR at least two clinical features such as Kayser-Fleischer rings, ceruloplasmin <20 mg/dL, liver biopsy consistent with Wilson disease, or 24‑hour urinary copper >40 μg/24 hr). Also include documentation of trial and failure/contraindication/intolerance to zinc products or justification that zinc is inappropriate, evidence of specialist involvement (gastroenterologist, hepatologist, or liver transplant physician), and any preferred-product-specific criteria per the member's plan. For cystinuria and lead poisoning, include the specific required labs/clinical findings and documentation of failure/intolerance to first-line measures or agents as described in the criteria.

Wilson's disease: genetic testing OR ≥2 clinical features (KF rings; ceruloplasmin <20 mg/dL; liver biopsy; 24‑hour urinary copper >40 μg/24 hr).
Wilson's disease: documentation of failure/contraindication/intolerance to zinc OR prescriber statement that zinc is inappropriate OR evidence patient has been started on penicillamine.
Wilson's disease: prescriber is or consulted with a gastroenterologist, hepatologist, or liver transplant physician.
Cystinuria: documentation of failure or inability to adhere to increased fluids, sodium/protein restriction, and urinary alkalinization.
Lead poisoning: blood lead level >44 μg/dL and documentation of failure/contraindication/intolerance to succimer and edetate calcium disodium.

Denial Risk

Not Covered Uses

Use of penicillamine products for any indication other than Wilson's disease, cystinuria, or lead poisoning is considered experimental, investigational, or unproven and therefore not covered.

Not covered: any use outside Wilson's disease, cystinuria, or lead poisoning.

Background

Penicillamine is a chelating agent used in specific clinical situations, including management of cystinuria and Wilson’s disease, and historically for severe active rheumatoid arthritis after failure of conventional therapy. Clinical guidance supports chelating agents (penicillamine or trientine) as initial therapy for symptomatic Wilson’s disease, while zinc may be used for presymptomatic or maintenance therapy. Brand formulations include Cuprimine (capsules) and Depen (tablets); generics are also available.

Definitions and Product Details

inv-14: Penicillamine products — Brand and generic formulations

Brand formulationsCuprimine — 250 mg capsules

Brand formulationsDepen — 250 mg tablets

UsePenicillamine products are chelating agents indicated for cystinuria, severe active rheumatoid arthritis after failure of conventional therapy, and Wilson's disease

inv-15: Wilson's disease diagnostic confirmation — Confirmed by genetic testing showing biallelic ATP7B pathogenic mutations or at least two clinical features (Kayser-Fleischer rings, ceru...

Diagnostic confirmation (genetic)Genetic testing confirming biallelic pathogenic ATP7B mutations

Diagnostic confirmation (clinical features)At least two of: Kayser-Fleischer rings; serum ceruloplasmin <20 mg/dL; liver biopsy consistent with Wilson disease; 24-hour urinary copper >40 μg/24 hours

Guideline sourcesCriteria referenced from AASLD (and EASL) guidance cited in policy